These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 23343178)

  • 21. The expression of p38, ERK1 and Bax proteins has increased during the treatment of newly diagnosed acute promyelocytic leukemia with arsenic trioxide.
    Mandegary A; Hosseini R; Ghaffari SH; Alimoghaddam K; Rostami S; Ghavamzadeh A; Ghahremani MH
    Ann Oncol; 2010 Sep; 21(9):1884-1890. PubMed ID: 20164150
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Metabolism of arsenic trioxide in acute promyelocytic leukemia cells.
    Khaleghian A; Ghaffari SH; Ahmadian S; Alimoghaddam K; Ghavamzadeh A
    J Cell Biochem; 2014 Oct; 115(10):1729-39. PubMed ID: 24819152
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Treatment of acute promyelocytic leukemia with arsenic trioxide: clinical and basic studies.
    Zhao WL; Chen SJ; Shen Y; Xu L; Cai X; Chen GQ; Shen ZX; Chen Z; Wang ZY
    Leuk Lymphoma; 2001; 42(6):1265-73. PubMed ID: 11911407
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Single-agent arsenic trioxide in the treatment of newly diagnosed acute promyelocytic leukemia: long-term follow-up data.
    Mathews V; George B; Chendamarai E; Lakshmi KM; Desire S; Balasubramanian P; Viswabandya A; Thirugnanam R; Abraham A; Shaji RV; Srivastava A; Chandy M
    J Clin Oncol; 2010 Aug; 28(24):3866-71. PubMed ID: 20644086
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Studies on the clinical efficacy and pharmacokinetics of low-dose arsenic trioxide in the treatment of relapsed acute promyelocytic leukemia: a comparison with conventional dosage.
    Shen Y; Shen ZX; Yan H; Chen J; Zeng XY; Li JM; Li XS; Wu W; Xiong SM; Zhao WL; Tang W; Wu F; Liu YF; Niu C; Wang ZY; Chen SJ; Chen Z
    Leukemia; 2001 May; 15(5):735-41. PubMed ID: 11368433
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparison of clinical outcomes of patients with relapsed acute promyelocytic leukemia induced with arsenic trioxide and consolidated with either an autologous stem cell transplant or an arsenic trioxide-based regimen.
    Thirugnanam R; George B; Chendamarai E; Lakshmi KM; Balasubramanian P; Viswabandya A; Srivastava A; Chandy M; Mathews V
    Biol Blood Marrow Transplant; 2009 Nov; 15(11):1479-84. PubMed ID: 19822309
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Characteristics and clinical influence factors of arsenic species in plasma and their role of arsenic species as predictors for clinical efficacy in acute promyelocytic leukemia (APL) patients treated with arsenic trioxide.
    Guo M; Zhou J; Fan S; Li L; Chen H; Lin L; Zhao Q; Wang X; Liu W; Wu Z; Hai X
    Expert Rev Clin Pharmacol; 2021 Apr; 14(4):503-512. PubMed ID: 33678104
    [No Abstract]   [Full Text] [Related]  

  • 28. Impact of arsenic trioxide in the treatment of acute promyelocytic leukemia.
    Lengfelder E; Hofmann WK; Nowak D
    Leukemia; 2012 Mar; 26(3):433-42. PubMed ID: 21904379
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia.
    Zhang P
    J Biol Regul Homeost Agents; 1999; 13(4):195-200. PubMed ID: 10703942
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Relapsed APL patient with variant NPM-RARalpha fusion responded to arsenic trioxide-based therapy and achieved long-term survival.
    Chen Y; Gu L; Zhou C; Wu X; Gao J; Li Q; Zhu Y; Jia C; Ma Z
    Int J Hematol; 2010 May; 91(4):708-10. PubMed ID: 20405253
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Anti-leukemic and anti-angiogenesis efficacy of arsenic trioxide in new cases of acute promyelocytic leukemia.
    Alimoghaddam K; Shariftabrizi A; Tavangar SM; Sanaat Z; Rostami S; Jahani M; Ghavamzadeh A
    Leuk Lymphoma; 2006 Jan; 47(1):81-8. PubMed ID: 16321832
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Expanding the use of arsenic trioxide: leukemias and beyond.
    Chen Z; Chen GQ; Shen ZX; Sun GL; Tong JH; Wang ZY; Chen SJ
    Semin Hematol; 2002 Apr; 39(2 Suppl 1):22-6. PubMed ID: 12012319
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Plasma cell-free DNA in patients with acute promyelocytic leukaemia treated with arsenic trioxide.
    Fujihara J; Nishimoto N; Takeshita H
    Ann Clin Biochem; 2024 Jul; 61(4):248-254. PubMed ID: 37944991
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Sudden death among patients with acute promyelocytic leukemia treated with arsenic trioxide.
    Westervelt P; Brown RA; Adkins DR; Khoury H; Curtin P; Hurd D; Luger SM; Ma MK; Ley TJ; DiPersio JF
    Blood; 2001 Jul; 98(2):266-71. PubMed ID: 11435292
    [TBL] [Abstract][Full Text] [Related]  

  • 35. United States multicenter study of arsenic trioxide in relapsed acute promyelocytic leukemia.
    Soignet SL; Frankel SR; Douer D; Tallman MS; Kantarjian H; Calleja E; Stone RM; Kalaycio M; Scheinberg DA; Steinherz P; Sievers EL; Coutré S; Dahlberg S; Ellison R; Warrell RP
    J Clin Oncol; 2001 Sep; 19(18):3852-60. PubMed ID: 11559723
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Phase II study of single-agent arsenic trioxide for the front-line therapy of acute promyelocytic leukemia.
    Ghavamzadeh A; Alimoghaddam K; Rostami S; Ghaffari SH; Jahani M; Iravani M; Mousavi SA; Bahar B; Jalili M
    J Clin Oncol; 2011 Jul; 29(20):2753-7. PubMed ID: 21646615
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The 12-year follow-up of survival, chronic adverse effects, and retention of arsenic in patients with acute promyelocytic leukemia.
    Zhu H; Hu J; Chen L; Zhou W; Li X; Wang L; Zhao X; Zhang Y; Zhao H; Wang A; Chen Y; Sun H; Chen Q; Chen Y; Zhao W; Mi J; Shen Z; Wang Z; Chen Z; Chen S; Li J
    Blood; 2016 Sep; 128(11):1525-8. PubMed ID: 27402972
    [No Abstract]   [Full Text] [Related]  

  • 38. Comparison of newly diagnosed and relapsed patients with acute promyelocytic leukemia treated with arsenic trioxide: insight into mechanisms of resistance.
    Chendamarai E; Ganesan S; Alex AA; Kamath V; Nair SC; Nellickal AJ; Janet NB; Srivastava V; Lakshmi KM; Viswabandya A; Abraham A; Aiyaz M; Mullapudi N; Mugasimangalam R; Padua RA; Chomienne C; Chandy M; Srivastava A; George B; Balasubramanian P; Mathews V
    PLoS One; 2015; 10(3):e0121912. PubMed ID: 25822503
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Arsenic: an old enemy now turned friend.
    Firkin F; Iland H
    Leuk Lymphoma; 2013 Sep; 54(9):1864-6. PubMed ID: 23550992
    [No Abstract]   [Full Text] [Related]  

  • 40. Torsemide increases arsenic concentrations by inhibition of multidrug resistance protein 4 in arsenic trioxide treated acute promyelocytic leukemia patients.
    Lv J; Wu M; Pang C; Duan R; Zhang H; Tian S; Yang H; Hai X
    Biomed Pharmacother; 2023 Jul; 163():114858. PubMed ID: 37172335
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.